Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18827512 | CRYSTALLINE FORMS OF A MENIN INHIBITOR | September 2024 | June 2025 | Allow | 9 | 2 | 0 | No | No |
| 18783334 | CYCLOPROPANE SKELETON MONOPHOSPHINE LIGANDS, PALLADIUM COMPLEXES THEREOF, PREPARATION METHODS AND APPLICATION | July 2024 | March 2025 | Allow | 8 | 0 | 1 | No | No |
| 18591732 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | February 2024 | May 2025 | Allow | 15 | 0 | 1 | No | No |
| 18427924 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | April 2024 | Allow | 3 | 0 | 0 | No | No |
| 18293947 | UREA AND MELAMINE PRODUCTION | January 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18395377 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | December 2023 | March 2024 | Allow | 3 | 1 | 0 | No | No |
| 18490700 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2023 | June 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18486813 | N'-(1-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18486921 | 2-ALKOXY[4,3:6,2-TERPYRIDINE]-3-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18378785 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 1 | No | No |
| 18379024 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18470331 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them | September 2023 | June 2025 | Allow | 21 | 1 | 1 | No | No |
| 18461093 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | September 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18221546 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | July 2023 | June 2025 | Allow | 23 | 1 | 1 | No | No |
| 18217874 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | July 2023 | December 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18211772 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | June 2023 | February 2024 | Allow | 8 | 0 | 0 | No | No |
| 18325214 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | May 2023 | October 2024 | Allow | 17 | 1 | 1 | No | No |
| 18195142 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | May 2023 | November 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18043987 | PHOSPHONATE PRODUCTS AND METHODS | March 2023 | November 2024 | Allow | 20 | 1 | 1 | No | No |
| 18090722 | SYSTEMS AND METHODS FOR INCREASING STABILITY OF DRONABINOL COMPOSITIONS | December 2022 | February 2025 | Allow | 25 | 2 | 1 | No | No |
| 18089065 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | December 2022 | May 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18070827 | PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDE | November 2022 | June 2024 | Allow | 18 | 1 | 1 | No | No |
| 18058655 | COMPOSITIONS AND METHODS FOR TREATING CANCER | November 2022 | October 2023 | Allow | 10 | 1 | 1 | No | No |
| 17992049 | Heterocyclic Compounds as RET Kinase Inhibitors | November 2022 | December 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17991558 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17990939 | SYNTHETIC PROCESS AND NOVEL INTERMEDIATES | November 2022 | March 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18053197 | HYDROCHLOROTHIAZIDE COMPOSITIONS | November 2022 | November 2023 | Allow | 12 | 2 | 1 | No | No |
| 17972220 | METHODS FOR THE SYNTHESIS OF ACTIVATED ETHYLFUMARATES AND THEIR USE AS INTERMEDIATES | October 2022 | September 2024 | Allow | 22 | 1 | 1 | No | No |
| 18047289 | COMPOSITIONS COMPRISING CIPROFLOXACIN AND CELECOXIB | October 2022 | June 2024 | Allow | 20 | 0 | 1 | No | No |
| 17960046 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | October 2022 | August 2024 | Allow | 22 | 2 | 1 | No | No |
| 17913883 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | September 2022 | March 2025 | Allow | 30 | 1 | 1 | No | No |
| 17950902 | Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound | September 2022 | December 2023 | Allow | 15 | 1 | 1 | No | No |
| 17946635 | Cannabinoid Product for Improvement of Sleep | September 2022 | January 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17929027 | PREPARATION OF A P2X3 ANTAGONIST | August 2022 | May 2025 | Allow | 33 | 0 | 0 | No | No |
| 17884154 | TERNARY PHOTOACTIVE LAYER COMPOSITION AND ORGANIC SOLAR CELL COMPRISING SAME | August 2022 | June 2025 | Allow | 34 | 0 | 1 | No | No |
| 17858917 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | July 2022 | September 2024 | Allow | 26 | 2 | 1 | No | No |
| 17810214 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | June 2022 | December 2023 | Allow | 17 | 0 | 1 | No | No |
| 17806395 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERS | June 2022 | April 2024 | Allow | 22 | 2 | 1 | No | No |
| 17804566 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | May 2022 | October 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17742843 | Solid Oral Dosage Forms Of Dexamethasone | May 2022 | December 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17739099 | NAIL HARDENING COMPOSITION AND METHOD OF USE | May 2022 | December 2022 | Allow | 7 | 1 | 1 | No | No |
| 17737273 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | May 2022 | September 2023 | Allow | 16 | 0 | 1 | No | No |
| 17737408 | MULTI-STAGE ESTERIFICATION PROCESS | May 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17737113 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT | May 2022 | July 2023 | Abandon | 15 | 0 | 1 | No | No |
| 17736644 | PROCESS FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID DIALKYL ESTER | May 2022 | July 2023 | Abandon | 15 | 0 | 1 | No | No |
| 17736688 | FLUORESCENT DYES CONTAINING BIS-BORON FUSED HETEROCYCLES AND USES IN SEQUENCING | May 2022 | March 2024 | Allow | 22 | 1 | 1 | No | No |
| 17755398 | Ion Channel Antagonists/Blockers and Uses Thereof | April 2022 | September 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17729287 | PROCESS FOR THE PRODUCTION OF FURFURAL USING A WATER IMMISCIBLE ORGANIC SOLVENT | April 2022 | August 2023 | Abandon | 15 | 1 | 1 | No | No |
| 17724717 | METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS | April 2022 | November 2023 | Allow | 19 | 1 | 1 | No | No |
| 17659736 | DECARBOXYLATED CANNABIS COMPOSITIONS AND METHODS OF MAKING THE SAME | April 2022 | November 2023 | Allow | 19 | 0 | 1 | No | No |
| 17722832 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | April 2022 | April 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17722654 | METHOD FOR PRODUCING ORGANOMETALLIC COMPOUND AND THIN FILM FABRICATED USING ORGANOMETALLIC COMPOUND OBTAINED THEREBY | April 2022 | April 2024 | Allow | 24 | 1 | 1 | No | No |
| 17721781 | EFFICIENT NEW PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDE | April 2022 | October 2022 | Allow | 6 | 0 | 1 | No | No |
| 17721133 | Synthesis And Characterization Of Air-Stable Iron-Based Catalysts For Suzuki-Miyaura Cross-Coupling Reactions Of Alkyl Halides And Aryl Boronic Esters | April 2022 | April 2024 | Allow | 24 | 2 | 1 | No | No |
| 17719727 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | April 2022 | April 2024 | Allow | 24 | 1 | 1 | No | No |
| 17715366 | COT MODULATORS AND METHODS OF USE THEREOF | April 2022 | July 2023 | Allow | 15 | 1 | 0 | No | No |
| 17701872 | FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF INDUCING FERROPTOSIS | March 2022 | November 2023 | Allow | 20 | 2 | 1 | No | No |
| 17698527 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SHIGA TOXICOSIS | March 2022 | July 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17694910 | Cannabinoid Product for Control of Pre-diabetic Markers | March 2022 | July 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17694287 | DIRECT SYNTHESIS OF CYCLIC CARBONATES USING CHOLINE CHLORIDE AS CATALYST UNDER MILD CONDITIONS | March 2022 | October 2023 | Allow | 19 | 0 | 1 | No | No |
| 17692026 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | March 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
| 17689925 | SYNTHESIS AND USE OF OXA-SPIRODIPHOSPHINE LIGAND | March 2022 | April 2024 | Allow | 26 | 2 | 1 | No | No |
| 17688101 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | March 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
| 17687002 | ION CHANNEL MODULATORS | March 2022 | February 2024 | Allow | 23 | 1 | 1 | No | No |
| 17587555 | MK2 INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | January 2022 | March 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17584590 | Choline Salt Forms of an HIV Capsid Inhibitor | January 2022 | July 2023 | Allow | 18 | 1 | 1 | No | No |
| 17584533 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | January 2022 | July 2023 | Allow | 18 | 1 | 1 | No | No |
| 17629543 | DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOF | January 2022 | June 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17574998 | Antibacterial Activity of Functionalized Dihydropyrimidines | January 2022 | February 2024 | Allow | 25 | 1 | 1 | No | No |
| 17567201 | SELECTIVE SMALL MOLECULE PEPTIDOMIMETIC MELANOCORTIN LIGANDS | January 2022 | November 2023 | Allow | 22 | 2 | 1 | No | No |
| 17564418 | AMORPHOUS SOLID DISPERSION FORMULATION | December 2021 | October 2023 | Allow | 22 | 1 | 1 | No | No |
| 17556827 | ORGANIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT, DISPLAY APPARATUS, PHOTOELECTRIC CONVERSION APPARATUS, ELECTRONIC APPARATUS, ILLUMINATION APPARATUS, MOVING OBJECT, AND EXPOSURE LIGHT SOURCE | December 2021 | October 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17553856 | HYBRID POLYVINYL ALCOHOL/ LINSEED DUAL CROSSLINKED NANOCOMPOSITE HYDROGEL LOADED WITH DOXYCYCLINE FOR THE PRODUCTION OF ACNE PATCHES | December 2021 | October 2024 | Allow | 34 | 3 | 1 | No | No |
| 17644604 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | December 2021 | September 2024 | Allow | 33 | 1 | 1 | No | No |
| 17549289 | COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION | December 2021 | July 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17546175 | HYDROCHLOROTHIAZIDE COMPOSITIONS | December 2021 | September 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17545053 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND FOOD WITH FUNCTION CLAIMS | December 2021 | September 2024 | Allow | 33 | 2 | 1 | No | No |
| 17543038 | PROCESS FOR THE PREPARATION OF UNSATURATED CARBOXYLIC ACIDS BY CARBONYLATION OF ALLYL ALCOHOLS AND THEIR ACYLATION PRODUCTS | December 2021 | July 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17534764 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | November 2021 | October 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17533592 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | November 2021 | September 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17532712 | BORATE ESTER COMPLEXES OF A-HYDROXY CARBOXYLIC ACIDS AND THEIR CONJUGATE BASE BUFFERS | November 2021 | February 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17522866 | Process for production of essentially pure delta-9-tetrahydrocannabinol | November 2021 | January 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17609135 | DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS | November 2021 | November 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17514387 | Cannabinoid Product for Assistance with Weight Loss | October 2021 | July 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17502975 | USE OF SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION IN BIOFILMS | October 2021 | November 2024 | Allow | 37 | 1 | 1 | No | No |
| 17500070 | Trytophan Metobolic Stimulation Compositions | October 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17450205 | FORMULATION OF A PAN-JAK INHIBITOR | October 2021 | June 2023 | Allow | 20 | 0 | 1 | No | No |
| 17601085 | PHENYLMETHYLPYRAZOLONE COMPOUND HAVING A NOVEL CRYSTAL FORM, AND METHOD FOR PRODUCING SAME | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17492282 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | October 2021 | December 2024 | Abandon | 38 | 3 | 1 | No | No |
| 17487279 | Histone Deacetylase Inhibitors and Methods of Use Thereof | September 2021 | December 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17598707 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | September 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17479869 | USE OF TACROLIMUS IN PREPARATION OF MEDICAMENT FOR INITIATING TISSUE REGENERATION FUNCTION | September 2021 | January 2024 | Allow | 28 | 1 | 1 | No | No |
| 17437192 | FUSED RING SUBSTITUTED AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION, AND USE THEREOF | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17467974 | METHOD FOR PURIFICATION OF TERPENOID AMINO ALCOHOL DERIVATIVES | September 2021 | June 2023 | Allow | 21 | 0 | 1 | No | No |
| 17435181 | METHOD FOR PREPARING TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOF | August 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17407276 | AMINE-BORANES AS BIFUNCTIONAL REAGENTS FOR DIRECT AMIDATION OF CARBOXYLIC ACIDS | August 2021 | April 2024 | Allow | 32 | 2 | 1 | No | No |
| 17405767 | PHYTONADIONE COMPOSITIONS AND RELATED METHODS | August 2021 | April 2024 | Allow | 32 | 1 | 1 | No | No |
| 17397457 | METHODS AND RELATED TOOLS FOR CBD CONVERSION TO THC | August 2021 | November 2024 | Allow | 40 | 2 | 1 | No | No |
| 17396717 | RIMEGEPANT FOR CGRP RELATED DISORDERS | August 2021 | March 2023 | Abandon | 20 | 1 | 1 | No | No |
| 17426931 | SOLID STATE FORMS OF OCLACITINIB MALEATE | July 2021 | September 2024 | Allow | 37 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KENYON, JOHN S.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KENYON, JOHN S works in Art Unit 1625 and has examined 810 patent applications in our dataset. With an allowance rate of 78.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner KENYON, JOHN S's allowance rate of 78.5% places them in the 39% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KENYON, JOHN S receive 1.56 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KENYON, JOHN S is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by KENYON, JOHN S. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.2% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 58.4% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 90.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.9% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.